Non-Invasive Skin Cancer Diagnosis Using Hyperspectral Imaging for In-Situ Clinical Support

• Published in: Journal of clinical medicine Vol. 9; no. 6; p. 1662
• Main Authors: Leon, Raquel, Martinez-Vega, Beatriz, Fabelo, Himar, Ortega, Samuel, Melian, Veronica, Castaño, Irene, Carretero, Gregorio, Almeida, Pablo, Garcia, Aday, Quevedo, Eduardo, Hernandez, Javier A, Clavo, Bernardino, M Callico, Gustavo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2020; MDPI
• Subjects: Cameras; Classification; Clinical medicine; Datasets; Medical diagnosis; Melanoma; Metastasis; Microscopy; Skin cancer; United States > US; Spain; clinical diagnosis; skin cancer; medical diagnostic imaging; hyperspectral imaging; biomedical optical imaging
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9061662

Skin cancer is one of the most common forms of cancer worldwide and its early detection its key to achieve an effective treatment of the lesion. Commonly, skin cancer diagnosis is based on dermatologist expertise and pathological assessment of biopsies. Although there are diagnosis aid systems based on morphological processing algorithms using conventional imaging, currently, these systems have reached their limit and are not able to outperform dermatologists. In this sense, hyperspectral (HS) imaging (HSI) arises as a new non-invasive technology able to facilitate the detection and classification of pigmented skin lesions (PSLs), employing the spectral properties of the captured sample within and beyond the human eye capabilities. This paper presents a research carried out to develop a dermatological acquisition system based on HSI, employing 125 spectral bands captured between 450 and 950 nm. A database composed of 76 HS PSL images from 61 patients was obtained and labeled and classified into benign and malignant classes. A processing framework is proposed for the automatic identification and classification of the PSL based on a combination of unsupervised and supervised algorithms. Sensitivity and specificity results of 87.5% and 100%, respectively, were obtained in the discrimination of malignant and benign PSLs. This preliminary study demonstrates, as a proof-of-concept, the potential of HSI technology to assist dermatologists in the discrimination of benign and malignant PSLs during clinical routine practice using a real-time and non-invasive hand-held device.